How new PET technology expands preclinical imaging capabilities.

How new PET technology expands preclinical imaging capabilities.

For over 20 years, preclinical PET imaging has relied on dual photon coincidence detection. While improvements in resolution and image contrast/noise ratios have since been achieved with time-of-flight (TOF) detection, this only works for clinical PET scanners. There have been no such improvements for small animal scanners. That’s why MILabs has stopped relying on dual photon coincidence detection and developed single-photon ultra-high-definition PET (U-PET) instead. The result: dramatically expanded PET capabilities as illustrated below.

Mouse Ultra-high definition PET yields the same visual acuity as Clinical PET

U-PET eliminates many of the blurring effects caused by dual photon coincidence imaging. E.g., random and scatter coincidences are being eliminated, blurring due to dual-photon non-collinearity is gone, magnified single-photon image projections further improve resolution, and contrast-noise ratios have become uniform throughout the object.
For the first time, it is now possible to reach sub-mm image resolutions for a wide variety of PET tracers – an essential capability for accurate image translation from rodents to the clinic. Read more…

Expanding preclinical PET with commonly used clinical PET tracers

Due to the large positron-range effect, several conventional tracers used in the clinic, such as ¹²⁴I, ⁸²Rb, and ⁷⁶Br, are not suitable for small animal imaging.
MILabs U-PET eliminates positron range blurring for these isotopes by detecting prompt photons emitted directly from the tracer molecules. As a result, sub-mm image resolutions can be obtained for these tracers as well. This includes the popular ⁸⁹Zr isotope for which U-PET eliminates image haze and produces crystal-clear sub-mm resolution images. Read more…

Concurrent imaging of multiple PET and PET/SPECT isotopes

U-PET makes simultaneous and quantitative imaging of co-injected PET tracers and multiple PET/SPECT tracers possible, at sub-mm resolutions. This unique capability allows studying multiple disease targets and therapy candidates in the same animal, with images co-registered in both space and time. As a result, you can reduce the number of animals needed for a study and increase information content. Read more…

Unlimited radiotherapy imaging and dosimetry applications

With the U-PET VECTor option, you can image virtually any alpha- and beta-emitting radiotherapy isotope. No surrogate markers are required, thus enabling direct theranostic imaging, including accurate dosimetry.
As illustrated, also for these high-energy isotopes, sub-mm resolutions can be obtained to accelerate radiotherapy translation from mouse cancer models to cancer patients in the clinic. Read more…

MILabs expands production facilities to meet continuing growth

Despite the current challenging economic environment, MILabs management feels confident that the company can maintain its annual double-digit growth: “Over the past years, MILabs has realized a steep growth (37% last year). Therefore, we decided to double our manufacturing and customer support space. This ensures us that we can keep meeting the expectations of the rapidly growing global user base of our multimodal synergistic imaging platforms. Indeed, this platform extends the applications of our technology into new market segments”, according to Frederik Beekman, CEO and founder of MILabs.
For further information: MILabs.com
Download the latest MILabs catalog

Follow MILabs on social media

LinkedIn
Facebook
Instagram
Twitter
YouTube

Forward

*|IF:REWARDS|* *|HTML:REWARDS|* *|END:IF|*

How new PET technology expands preclinical imaging capabilities.

RSNA 2021

Global Sales, Service & Support

Distributors